NCT07450833 2026-03-05
BOOST
Benfovir AG
Phase 1 Completed
Clinical Trials
18 trialsNCT04977024 2026-02-11
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
GeoVax, Inc.
Phase 2 Active not recruiting
NCT05119855 2026-02-05
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03305341 2025-06-11
COVSP-BCG
Medicine Invention Design, Inc
Phase EARLY_PHASE1 Active not recruiting
NCT06469138 2025-01-29
8479217
BerGenBio ASA
Phase 1 Completed
NCT04404361 2024-06-05
PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
CTI BioPharma
Phase 2 Terminated
NCT04426201 2024-04-11
ILIAD-7-US-O
Revimmune
Phase 2 Terminated
NCT05125562 2024-02-13
Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19
Direct Biologics, LLC
Phase 2 Withdrawn
NCT04358406 2023-11-28
Rhu-pGSN for Severe Covid-19 Pneumonia
BioAegis Therapeutics Inc.
Phase 2 Completed
NCT05303376 2023-09-13
Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness
Immune Biosolutions Inc
Phase 1/2 Completed
NCT05438498 2023-09-08
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
MediMergent, LLC
Phase 3 Terminated
NCT04733833 2023-02-01
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase 2 Completed
NCT05371275 2022-11-07
CDK6COV
biotx.ai GmbH
Phase 2 Withdrawn
NCT04803227 2022-01-04
Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19
Histogen
Phase 1 Terminated
NCT04446429 2021-12-10
Anti-Androgen Treatment for COVID-19
Applied Biology, Inc.
Phase NA Completed
NCT04953234 2021-07-07
Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge
NovoCure Ltd.
Phase NA Completed
NCT04419623 2021-05-12
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
Telios Pharma, Inc.
Phase 1 Completed
NCT04564040 2020-12-29
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
AstraZeneca
Phase 1 Completed